Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Ten subjects will be enrolled in the study. Each subject will have their left and right
forehead randomly assigned to receive 4 units of PrabotulinumtoxinA-xvfs or
OnabotulinumtoxinA. Subjects will be reassessed at 2 weeks for evaluation of rhytide
diminution around each injection point to assess relative diffusion of each drug in the
forehead.